<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01598844</url>
  </required_header>
  <id_info>
    <org_study_id>JV03PMS</org_study_id>
    <nct_id>NCT01598844</nct_id>
  </id_info>
  <brief_title>JUPITER Study: Transapical Aortic Valve Implantation for Aortic Regurgitation</brief_title>
  <acronym>JUPITER</acronym>
  <official_title>The JenaValve&quot; EvalUation of Long Term Performance and Safety In PaTients With SEvere Aortic Stenosis oR Aortic Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JenaValve Technology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universit채tsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>JenaValve Technology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to observe longterm performance and safety of the JenaValve&#xD;
      TAVI system, in routine medical and everyday conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the long term safety and effectiveness of the&#xD;
      CE-marked JenaValve System Transapical in an elderly patient population with severe aortic&#xD;
      stenosis and/or aortic insufficiency who are at high risk for open surgical aortic valve&#xD;
      replacement.&#xD;
&#xD;
      The target study population will consist of elderly patients suffering from severe&#xD;
      symptomatic degenerative aortic valve stenosis and/or aortic insufficiency who show an&#xD;
      increased risk for an open aortic valve replacement surgery due to existing co-morbidities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2012</start_date>
  <completion_date type="Actual">July 31, 2018</completion_date>
  <primary_completion_date type="Actual">August 27, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 day</time_frame>
    <description>30-day mortality of procedure is defined as all deaths within 30 days after implantation of the JenaValve prosthesis irrespective of the underlying cause of death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoints</measure>
    <time_frame>peri- and post-operatively and at 3, 6, 12, 24 and 36 months</time_frame>
    <description>All-cause mortality&#xD;
Cardiovascular mortality&#xD;
Major stroke&#xD;
Life-threatening or disabling bleeding&#xD;
Major bleeding&#xD;
Acute kidney injury&#xD;
Myocardial infarction&#xD;
Major vascular complication&#xD;
Mechanical coronary obstruction&#xD;
Prosthetic valve thrombus&#xD;
Prosthetic valve endocarditis&#xD;
Conduction disturbance and cardiac arrhythmia&#xD;
Necessity of permanent pacemaker implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>Index Procedure and Immediate Post-operative</time_frame>
    <description>The following parameters will be collected to assess device success:&#xD;
Successful vascular access, delivery and deployment of the device successful retrieval of the device&#xD;
Correct position of the device in the proper anatomical location&#xD;
Intended performance of the prosthetic heart valve:&#xD;
Only one valve implanted in proper anatomical position</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Effectiveness</measure>
    <time_frame>Prior to discharge, at 3, 6, 12, 24 and 36 months</time_frame>
    <description>The following parameters will assess effectiveness:&#xD;
Transvalvular aortic peak pressure gradient&#xD;
Transvalvular aortic mean pressure gradient&#xD;
Effective aortic valve area&#xD;
Paravalvular regurgitation coded according to VARC&#xD;
Transvalvular regurgitation coded according to VARC&#xD;
No clinically significant valve migration/dislocation&#xD;
Absence of mechanical coronary obstruction&#xD;
Functional improvement assessment by NYHA functional classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12 Survey of Quality of Life</measure>
    <time_frame>at 12 months</time_frame>
    <description>The SF-12 health survey to measure mental and physical health of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Safety Endpoint</measure>
    <time_frame>at 30 days</time_frame>
    <description>A combined safety endpoint will be assessed at 30 days consisting of the following variables:&#xD;
All-cause mortality&#xD;
Major stroke&#xD;
Acute kidney injury (Stage 3)&#xD;
Life-threatening or disabling bleeding&#xD;
Major vascular complication&#xD;
Peri-procedural myocardial infarction&#xD;
Repeat surgical or interventional procedure for valve-related dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Efficacy Endpoint</measure>
    <time_frame>at 12 months</time_frame>
    <description>A combined efficacy endpoint will be assessed consisting of the following variables:&#xD;
All-cause mortality (after &gt; 30 days)&#xD;
Failure of current therapy for AS, requiring hospitalization for symptoms of valve-related or cardiac decompensation&#xD;
Prosthetic heart valve dysfunction</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">210</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Aortic Insufficiency</condition>
  <condition>Aortic Regurgitation</condition>
  <arm_group>
    <arm_group_label>High risk patients with aortic stenosis</arm_group_label>
    <description>Transapical aortic valve implantation using a transcatheter heart valve for aortic stenosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High risk patients with AI</arm_group_label>
    <description>Transapical aortic valve implantation using a transcatheter heart valve for aortic regurgitation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter aortic valve replacement</intervention_name>
    <description>Transcatheter aortic valve replacement via a transapical access</description>
    <arm_group_label>High risk patients with AI</arm_group_label>
    <arm_group_label>High risk patients with aortic stenosis</arm_group_label>
    <other_name>The JenaValve TAVI System</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe aortic stenosis or with severe aortic insufficiency and an increased&#xD;
        risk for an open aortic valve replacement surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients suitable for TAVI with the JenaValve according to instructions for use&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unsuitable for TAVI with the JenaValve according to instructions for use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olaf Wendler, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital, London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hendrik Treede, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Heart Center Hamburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Dresden, Universit채tsklinik an der Technischen Universit채t Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Heart Centre</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit채res Herzzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum der Universit채t</name>
      <address>
        <city>K철ln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig - Universit채tsklinik</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum M체nchen</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum des St채dtischen Klinikums M체nchen</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Kreislaufzentrum Rotenburg (Fulda)</name>
      <address>
        <city>Rotenburg An Der Fulda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Bosch Krankenhaus Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit채tsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Mieres J, Men챕ndez M, Fern찼ndez-Pereira C, Rubio M, Rodr챠guez AE. Transapical Implantation of a 2nd-Generation JenaValve Device in Patient with Extremely High Surgical Risk. Case Rep Cardiol. 2015;2015:458151. doi: 10.1155/2015/458151. Epub 2015 Aug 4.</citation>
    <PMID>26346128</PMID>
  </reference>
  <reference>
    <citation>Seiffert M, Bader R, Kappert U, Rastan A, Krapf S, Bleiziffer S, Hofmann S, Arnold M, Kallenbach K, Conradi L, Schlingloff F, Wilbring M, Sch채fer U, Diemert P, Treede H. Initial German experience with transapical implantation of a second-generation transcatheter heart valve for the treatment of aortic regurgitation. JACC Cardiovasc Interv. 2014 Oct;7(10):1168-74. doi: 10.1016/j.jcin.2014.05.014. Epub 2014 Aug 13.</citation>
    <PMID>25129672</PMID>
  </reference>
  <results_reference>
    <citation>Silaschi M, Treede H, Rastan AJ, Baumbach H, Beyersdorf F, Kappert U, Eichinger W, R체ter F, de Kroon TL, Lange R, Ensminger S, Wendler O. The JUPITER registry: 1-year results of transapical aortic valve implantation using a second-generation transcatheter heart valve in patients with aortic stenosis. Eur J Cardiothorac Surg. 2016 Nov;50(5):874-881. Epub 2016 May 30.</citation>
    <PMID>27242354</PMID>
  </results_reference>
  <results_reference>
    <citation>Silaschi M, Conradi L, Wendler O, Schlingloff F, Kappert U, Rastan AJ, Baumbach H, Holzhey D, Eichinger W, Bader R, Treede H. The JUPITER registry: One-year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation. Catheter Cardiovasc Interv. 2018 Jun;91(7):1345-1351. doi: 10.1002/ccd.27370. Epub 2017 Nov 24.</citation>
    <PMID>29171730</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 11, 2012</study_first_submitted>
  <study_first_submitted_qc>May 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2012</study_first_posted>
  <last_update_submitted>November 22, 2020</last_update_submitted>
  <last_update_submitted_qc>November 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

